| 臺大學術典藏 |
2020-11-27T03:28:36Z |
Clinical Efficacy and Post-Treatment Seromarkers Associated with the Risk of Hepatocellular Carcinoma among Chronic Hepatitis C Patients
|
Lee M.-H.; Huang C.-F.; Lai H.-C.; Lin C.-Y.; Dai C.-Y.; Liu C.-J.; Wang J.-H.; Huang J.-F.; Su W.-P.; Yang H.-C.; Kee K.-M.; Yeh M.-L.; Chuang P.-H.; Hsu S.-J.; Huang C.-I.; Kao J.-T.; CHIEH-CHANG CHEN; Chen S.-H.; Jeng W.-J.; Yang H.-I.; Yuan Y.; Lu S.-N.; Sheen I.-S.; Liu C.-H.; Peng C.-Y.; Kao J.-H.; Yu M.-L.; Chuang W.-L.; Chen C.-J. |
| 臺大學術典藏 |
2020-11-03T08:19:39Z |
Elbasvir/grazoprevir for hepatitis C virus genotype 1b East-Asian patients receiving hemodialysis
|
CHEN-HUA LIU; Peng C.-Y.; Fang Y.-J.; Kao W.-Y.; Yang S.-S.; Lin C.-K.; Lai H.-C.; Su W.-P.; Fang S.-U.; Chang C.-C.; Su T.-H.; Liu C.-J.; Chen P.-J.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2020-08-13T06:34:06Z |
Epidermal growth factor receptor mutations in needle biopsy/aspiration samples predict response to gefitinib therapy and survival of patients with advanced nonsmall cell lung cancer
|
JIN-YUAN SHIH; Gow C.-H.; Yu C.-J.; Yang C.-H.; Chang Y.-L.; Tsai M.-F.; Hsu Y.-C.; Chen K.-Y.; Su W.-P.; Yang P.-C. |
| 臺大學術典藏 |
2020-08-13T06:34:06Z |
Gefitinib treatment for non-small cell lung cancer - A study including patients with poor performance status
|
Su W.-P.; Yang C.-H.; Yu C.-J.; JIN-YUAN SHIH; Hsu C.; Yang P.-C.; Su W.-P.;Yang C.-H.;Yu C.-J.;Jin-Yuan Shih;Hsu C.;Yang P.-C. |
| 臺大學術典藏 |
2020-08-13T06:34:05Z |
Survival outcome and predictors of gefitinib antitumor activity in East Asian chemonaive patients with advanced nonsmall cell lung cancer
|
Lin C.-P.; Su W.-P.; Gow C.-H.; Hsu C.; Chang G.-C.; Yang P.-C.; Yu C.-J.; Yang T.-Y.; Yang C.-H.; JIN-YUAN SHIH; Chen K.-C. |
| 臺大學術典藏 |
2020-08-12T06:35:50Z |
Gefitinib treatment for non-small cell lung cancer - A study including patients with poor performance status
|
Su W.-P.;Yang C.-H.;Chong-Jen Yu;Shih J.-Y.;Hsu C.;Yang P.-C.; Su W.-P.; Yang C.-H.; CHONG-JEN YU; Shih J.-Y.; Hsu C.; Yang P.-C. |
| 臺大學術典藏 |
2020-08-06T07:52:05Z |
Functional MR imaging of tumor angiogenesis predicts outcome of patients with acute myeloid leukemia [5]
|
Su W.-P.; Chan W.-K.; Yang P.-C.; TIFFANY TING-FANG SHIH; Tien H.-F.; Liu C.-Y. |
| 臺大學術典藏 |
2020-05-26T09:27:27Z |
Epidermal growth factor receptor mutations in needle biopsy/aspiration samples predict response to gefitinib therapy and survival of patients with advanced nonsmall cell lung cancer
|
Shih J.-Y;Gow C.-H;Yu C.-J;Chih-Hsin Yang;Chang Y.-L;Tsai M.-F;Hsu Y.-C;Chen K.-Y;Su W.-P;Yang P.-C.; Shih J.-Y; Gow C.-H; Yu C.-J; CHIH-HSIN YANG; Chang Y.-L; Tsai M.-F; Hsu Y.-C; Chen K.-Y; Su W.-P; Yang P.-C. |
| 臺大學術典藏 |
2020-05-26T09:27:27Z |
Gefitinib treatment for non-small cell lung cancer - A study including patients with poor performance status
|
Su W.-P;Chih-Hsin Yang;Yu C.-J;Shih J.-Y;Hsu C;Yang P.-C.; Su W.-P; CHIH-HSIN YANG; Yu C.-J; Shih J.-Y; Hsu C; Yang P.-C. |
| 臺大學術典藏 |
2020-05-26T09:27:26Z |
Survival outcome and predictors of gefitinib antitumor activity in East Asian chemonaive patients with advanced nonsmall cell lung cancer
|
Chih-Hsin Yang;Shih J.-Y;Chen K.-C;Yu C.-J;Yang T.-Y;Lin C.-P;Su W.-P;Gow C.-H;Hsu C;Chang G.-C;Yang P.-C.; CHIH-HSIN YANG; Shih J.-Y; Chen K.-C; Yu C.-J; Yang T.-Y; Lin C.-P; Su W.-P; Gow C.-H; Hsu C; Chang G.-C; Yang P.-C. |
| 臺大學術典藏 |
2020-05-26T09:26:57Z |
A phase i study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies
|
Lin C.-C;Su W.-C;Yen C.-J;Hsu C.-H;Su W.-P;Yeh K.-H;Lu Y.-S;Cheng A.-L;Huang D.C.-L;Fritsch H;Voss F;Taube T;Chih-Hsin Yang; Lin C.-C; Su W.-C; Yen C.-J; Hsu C.-H; Su W.-P; Yeh K.-H; Lu Y.-S; Cheng A.-L; Huang D.C.-L; Fritsch H; Voss F; Taube T; CHIH-HSIN YANG |
| 臺大學術典藏 |
2020-05-25T07:35:22Z |
A phase i study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies
|
Chia-Chi Lin; Su W.-C; Yen C.-J; Hsu C.-H; Su W.-P; Yeh K.-H; Lu Y.-S; Cheng A.-L; Huang D.C.-L; Fritsch H; Voss F; Taube T; Yang J.C.-H. |
| 臺大學術典藏 |
2020-05-25T07:35:14Z |
Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial
|
Aarts M.J.B; Erdkamp F.L.G; Blaisse R.J.B; Flores C.L.U; Cort?s L.V; Lee Y.-G; Kim Y.J; Rha S.Y; Ferrario C; Sengeloev L; Jensen N.V; Thibault C; Laguerre B; Joly F; Flechon A; Culine S; Becht C; Niegisch G; St?ckle M; Grimm M.-O; Gakis G; Schultze-Seemann W; Kalofonos H; Mavroudis D; Papandreou C; Karavasilis V; R?v?sz J; Geczi L; Rosenbaum E; Leibowitz-Amit R; Kejzman D; Sarid D; Scagliotti G.V; Bracarda S; Massari F; Osawa T; Miyajima N; Shinohara N; Fukuta F; Ohyama C; Obara W; Yamashita S; Tomita Y; Kawai K; Fukasawa S; Oyama M; Yonese J; Nagata M; Uemura M; Nishimura K; Kawakita M; Tsunemori H; Hashine K; Inokuchi J; Yokomizo A; Nagamori S; Lee H.J; Park S.H; Alekseev B; Necchi A; G?czi L; Ou Y.-C; Coskun H.S; Su W.-P; Hegemann M; Percent I.J; Lee J.-L; Tucci M; Semenov A; Laestadius F; Peer A; Tortora G; Safina S; del Muro X.G; Rodriguez-Vida A; Cicin I; Harputluoglu H; Widau R.C; Liepa A.M; Walgren R.A; Hamid O; Zimmermann A.H; Bell-McGuinn K.M; Powles T; Wong S.-L.S; Tan T.H; Hovey E.J; Clay T.D; Ng S.S.W; Rutten A; Machiels J.-P; Dumez H; Cheng S.Y.-S; Petrylak D.P; de Wit R; Chi K.N; Drakaki A; Sternberg C.N; Nishiyama H; Castellano D; Hussain S; Fl?chon A; Bamias A; Yu E.Y; van der Heijden M.S; Matsubara N; Vaishampayan U.; Aragon-Ching J; Tagawa S; Lawler W; Lowe T; Herms B; Hainsworth J; Cultrera J; Schwarz J; Flaig T; Pan C.X; Wojcik-Tomaszewska J; Tomczak P; Sikora-Kupis B; Schenker M; Herzal A.A; Udrea A.A; Karlov P; Fomkin R; Pulido E.G; Mignorance J.I.D; Gauna D.C; Rodr?guez-Vida A; Su Y.-L; Lin C.-L; Chia-Chi Lin; Yeh S.-P; ?i?in I; Erman M; Urun Y; Golovko Y; Bondarenko I; Sinielnikov I; Crabb S; Syndikus I; Huddart R; Sundar S; Chowdhury S; Sarwar N |
| 臺大學術典藏 |
2020-05-25T07:35:03Z |
Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial
|
Petrylak D.P; de Wit R; Chi K.N; Drakaki A; Sternberg C.N; Nishiyama H; Castellano D; Hussain S.A; Fl?chon A; Bamias A; Yu E.Y; van der Heijden M.S; Matsubara N; Alekseev B; Necchi A; G?czi L; Ou Y.-C; Coskun H.S; Su W.-P; Bedke J; Gakis G; Percent I.J; Lee J.-L; Tucci M; Semenov A; Laestadius F; Peer A; Tortora G; Safina S; Garcia del Muro X; Rodriguez-Vida A; Cicin I; Harputluoglu H; Tagawa S.T; Vaishampayan U; Aragon-Ching J.B; Hamid O; Liepa A.M; Wijayawardana S; Russo F; Walgren R.A; Zimmermann A.H; Hozak R.R; Bell-McGuinn K.M; Powles T; Wong S.-L.S; Tan T.H; Hovey E.J; Clay T.D; Wan Ng S.S; Rutten A; Machiels J.-P; Dumez H; Cheng S.Y.-S; Ferrario C; Sengeloev L; Jensen N.V; Thibault C; Laguerre B; Joly F; Culine S; Becht C; Niegisch G; St?ckle M; Grimm M.-O; Schwentner C.A; Schultze-Seemann W; Kalofonos H; Mavroudis D; Papandreou C; Karavasilis V; R?v?sz J; Rosenbaum E; Leibowitz-Amit R; Kejzman D; Sarid D; Scagliotti G.V; Bracarda S; Massari F; Osawa T; Miyajima N; Shinohara N; Fukuta F; Ohyama C; Obara W; Yamashita S; Tomita Y; Kawai K; Fukasawa S; Oyama M; Yonese J; Nagata M; Uemura M; Nishimura K; Kawakita M; Tsunemori H; Hashine K; Inokuchi J; Yokomizo A; Nagamori S; Lee H.J; Park S.H; Rha S.Y; Kim Y.J; Lee Y.-G; Vazquez Cort?s L; Lorena Urzua Flores C; Blaisse R.J.B; Erdkamp F.L.G; Aarts M.J.B; Wojcik-Tomaszewska J; Tomczak P; Sikora-Kupis B; Schenker M; Herzal A.A; Udrea A.A; Karlov P; Fomkin R; Gajate Borau P; Grande E; Delgado Mignorance J.I; Su Y.-L; Li J.-R; Lin C.-L; Chia-Chi Lin; Yeh S.-P; Erman M; Urun Y; Golovko Y; Bondarenko I; Sinielnikov I; Crabb S.J; Syndikus I; Huddart R; Sundar S; Chowdhury S; Sarwar N; Flaig T.W; Pan C.X; Schwarz J.K; Cultrera J.L; Acs P.I; Hainsworth J.D; Herms B.T; Lawler W.E; Lowe T.E. |
| 臺大學術典藏 |
2020-05-25T06:52:08Z |
Long-term hepatic consequences of chemotherapy-related HBV reactivation in lymphoma patients
|
Su W.-P;Wen C.-C;Hsiung C.A;Su I.-J;Cheng A.-L;Chang M.-C;Tsao C.-J;Kao W.-Y;Uen W.-C;Hsu C.-H;Yen-Shen Lu;Tien H.-F;Chao T.-Y;Chen L.-T;Whang-Peng J;Chen P.-J.; Su W.-P; Wen C.-C; Hsiung C.A; Su I.-J; Cheng A.-L; Chang M.-C; Tsao C.-J; Kao W.-Y; Uen W.-C; Hsu C.-H; YEN-SHEN LU; Tien H.-F; Chao T.-Y; Chen L.-T; Whang-Peng J; Chen P.-J. |
| 臺大學術典藏 |
2020-05-25T06:51:54Z |
A phase i study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies
|
Lin C.-C;Su W.-C;Yen C.-J;Hsu C.-H;Su W.-P;Yeh K.-H;Yen-Shen Lu;Cheng A.-L;Huang D.C.-L;Fritsch H;Voss F;Taube T;Yang J.C.-H.; Lin C.-C; Su W.-C; Yen C.-J; Hsu C.-H; Su W.-P; Yeh K.-H; YEN-SHEN LU; Cheng A.-L; Huang D.C.-L; Fritsch H; Voss F; Taube T; Yang J.C.-H. |
| 臺大學術典藏 |
2020-04-28T07:25:19Z |
A phase i study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies
|
Lin C.-C.;Su W.-C.;Yen C.-J.;Chih-Hung Hsu;Su W.-P.;Yeh K.-H.;Lu Y.-S.;Cheng A.-L.;Huang D.C.-L.;Fritsch H.;Voss F.;Taube T.;Yang J.C.-H.; Lin C.-C.; Su W.-C.; Yen C.-J.; CHIH-HUNG HSU; Su W.-P.; Yeh K.-H.; Lu Y.-S.; Cheng A.-L.; Huang D.C.-L.; Fritsch H.; Voss F.; Taube T.; Yang J.C.-H. |
| 臺大學術典藏 |
2020-04-10T12:51:27Z |
Gefitinib treatment for non-small cell lung cancer - A study including patients with poor performance status
|
Su W.-P.;Yang C.-H.;Yu C.-J.;Shih J.-Y.;Chiun Hsu;Yang P.-C.; Su W.-P.; Yang C.-H.; Yu C.-J.; Shih J.-Y.; Chiun Hsu; Yang P.-C. |
| 臺大學術典藏 |
2020-04-10T12:51:25Z |
Survival outcome and predictors of gefitinib antitumor activity in East Asian chemonaive patients with advanced nonsmall cell lung cancer
|
Gow C.-H.; Chiun Hsu; Chang G.-C.; Yang P.-C.; Su W.-P.; Lin C.-P.; Yang T.-Y.; Yu C.-J.; Chen K.-C.; Shih J.-Y.; Yang C.-H.; Yang C.-H.;Shih J.-Y.;Chen K.-C.;Yu C.-J.;Yang T.-Y.;Lin C.-P.;Su W.-P.;Gow C.-H.;Chiun Hsu;Chang G.-C.;Yang P.-C. |
| 臺大學術典藏 |
2020-03-26T06:54:22Z |
Signal transducer and activator of transcription 3 as molecular therapy for non-small-cell lung cancer
|
Wang C.-Y.; Chao T.-T.; Tai W.-T.; Chang F.-Y.; Su W.-P.; Chen Y.-L.; Chen P.-T.; Weng C.-Y.; ANG YUAN; Shiau C.-W.; Yu C.-J.; Chen K.-F. |
| 臺大學術典藏 |
2020-03-07T06:56:54Z |
Epidermal growth factor receptor mutations in needle biopsy/aspiration samples predict response to gefitinib therapy and survival of patients with advanced nonsmall cell lung cancer
|
Shih J.-Y.;Gow C.-H.;Yu C.-J.;Yang C.-H.;Yih-Leong Chang;Tsai M.-F.;Hsu Y.-C.;Chen K.-Y.;Su W.-P.;Yang P.-C.; Shih J.-Y.; Gow C.-H.; Yu C.-J.; Yang C.-H.; YIH-LEONG CHANG; Tsai M.-F.; Hsu Y.-C.; Chen K.-Y.; Su W.-P.; Yang P.-C. |
| 臺大學術典藏 |
2020-03-06T05:26:38Z |
Epidermal growth factor receptor mutations in needle biopsy/aspiration samples predict response to gefitinib therapy and survival of patients with advanced nonsmall cell lung cancer
|
Shih J.-Y.; Gow C.-H.; Yu C.-J.; Yang C.-H.; YIH-LEONG CHANG; Tsai M.-F.; Hsu Y.-C.; Chen K.-Y.; Su W.-P.; Yang P.-C. |
| 臺大學術典藏 |
2020-01-22T07:46:24Z |
Combined interactions of plant homeodomain and chromodomain regulate NuA4 activity at DNA double-strand breaks
|
MAU-SUN CHANG; Liaw H.; Myung K.; Wu W.-S.; Hung P.-C.; Hung J.-J.; Yang W.-B.; Chang M.-S.; Chen Y.-C.; Shih M.-Y.; Lin Y.-J.; Jiang Z.-D.; Chang S.-B.; Lin J.-Y.; Chia L.-C.; Hsu S.-H.; Su W.-P.;Hsu S.-H.;Chia L.-C.;Lin J.-Y.;Chang S.-B.;Jiang Z.-D.;Lin Y.-J.;Shih M.-Y.;Chen Y.-C.;Chang M.-S.;Yang W.-B.;Hung J.-J.;Hung P.-C.;Wu W.-S.;Myung K.;Liaw H.; Su W.-P. |
| 國立成功大學 |
2020 |
The HLTF–PARP1 interaction in the progression and stability of damaged replication forks caused by methyl methanesulfonate
|
Shiu, J.-L.;Wu, C.-K.;Chang, S.-B.;Sun, Y.-J.;Chen, Y.-J.;Lai, C.-C.;Chiu, W.-T.;Chang, W.-T.;Myung, K.;Su, W.-P.;Liaw, H. |
| 國立成功大學 |
2020 |
Rich p-type-doping phenomena in boron-substituted silicene systems: Boron-substituted silicene
|
Pham, H.D.;Su, W.-P.;Nguyen, T.D.H.;Tran, N.T.T.;Lin, M.-F. |
